XMT-2056, a HER2-Targeted Immunosynthen Sting Agonist Antibody-Drug Conjugate, Induces Anti-tumor Activity at Low Doses in Preclinical Models
Tumor Cell-Directed STING Agonist Antibody Drug Conjugates Induce Type III Interferons and Anti-Tumor Innate Immune Responses
Discovery and Optimization of a STING Agonist Platform for Application in Antibody Drug Conjugates
XMT-2056, a HER2-Directed STING Agonist Antibody-Drug Conjugate, Exhibits ADCC Function that Synergizes with STING Pathway Activation and Contributes to Anti-tumor Responses
XMT-2056: A HER-2 Targeted Immunosynthen STING Agonist Antibody Drug Conjugate
August, 2022
XMT-2056: A HER-2 Targeted Immunosynthen STING Agonist Antibody Drug Conjugate
August, 2022
XMT-2056, a HER2-Targeted Immunosynthen STING-Agonist Antibody-Drug Conjugate, Binds a Novel Epitope of HER2 and Shows Increased Anti-tumor Activity in Combination With Trastuzumab and Pertuzumab
April, 2022
Tumor Cell-Targeted STING-Agonist Antibody-Drug Conjugates Achieve Potential Anti-tumor Activity by Delivering STING Agonist Specifically to Tumor Cells and FcγRi-Expressing Subset of Myeloid Cells
April, 2022